Henna[Henna]NCT06832501
Effectiveness of the Henna Application in Patients With Hand-Foot Syndrome: Nested Case-Control Study
An observational study of Henna and Hand-Foot Syndrome, run by Hacettepe University at 1 site in Turkey (Türkiye).
Trial summary
Introduction: There is an explanation that there is a connection between the application of henna and the occurrence of hand-foot syndrome, and the purpose and progression of this interaction. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Henna, Hand-Foot Syndrome, Case-Control Study
- What is being tested?
- Henna
- How many people
- 84 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Oct 2018to 31 Dec 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: In the data collection process, 28 patients received capecitabine treatment at the Hacettepe University Hospital of Oncology meeting the research criteria and two patients (n=56, who received the test) who met the inclusion criteria served as the control group for each case. (1:2). Controls were matched with patients in a ratio of two to one depending on age at collection of samples (+3), gender, body surface area index, and skin type data. Minimum number of samples achieved under at least 5% type error and at least 95% power condition. The study used the initial non-development of EAS as a criterion for the HFS scale score, which was studied between "grade 0" and "grade 3" according to the NIC-CTCAE criteria, and was between 18 and 65 years of age.
Who may be able to join
- Would be getting capecitabine as chemotherapy,
- Were aged between 18 and 65,
- Had a diagnosis of either breast or cancer of the colorectal
- Were willing to communicate, literate, and were informed about their diagnosis,
- Were not using psychotropic drugs, anxiolytic, antidepressant, analgesic, or sedative medications,
- Did not have any type of neurological condition or neuropathy, and vi. consented to participate in the study voluntarily.
Who cannot join
- Were undergoing radiation,
- Were taking supplements such as vitamin E,
- Had previously had capecitabine treatment,
- Had damage to the skin on their hands or feet,
- Were unwilling to voluntarily engage in the trial.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Hacettepe University
Ankara, Adnan Saygun, 06100
About this study
Introduction: There is an explanation that there is a connection between the application of henna and the occurrence of hand-foot syndrome, and the purpose and progression of this interaction. This nested case-control study of participants who underwent capecitabine therapy were breast and colorectal cancer was carried out to prospectively investigate the relationship of hand-foot syndrome with the henna application.
Method: Nested Case-Control (NCC) design within a longitudinal observational prospective cohort study in the setting of an oncology clinic. The primary outcome was hand-foot syndrome from in-hospital interviews and medical record reviews. In the data collection process, 84 patients received capecitabine and two patients (1:2) who met the inclusion criteria served as the control group (n=56, who received the test) for each case (n=28). The case and control groups were followed for 12 weeks. HFS-14 Scale and EORTC QLQ-C30 Quality of Life were conducted on the baseline, first follow-up (T1=day 21), and second follow-up (T2=day 63) cycles of chemotherapy. We used a non-parametric signed-rank test to test the median of paired differences.
Read the detailed description
Capecitabine is among the most effective treatments for metastatic or late-stage breast cancer. It is also another treatment approach for colorectal cancer. Capecitabine is a high-concentration 5-FU prodrug planned for thymidine phosphorylase enzyme primarily for two cancer types [1, 2]. Hand-foot syndrome (HFS), increasing skin pigmentation, diarrhea, nausea-vomiting, and fatigue are common side effects of the capecitabine treatment. According to phases 1 and 2 studies, the most common side effect of capecitabine is HFS, with a frequency that ranges from 10 to 50.7% [3]. HFS is a serious condition characterized by the accumulation of symmetrical, sharply contained, erythematous, edematous plaques, particularly on the lateral parts of the fingers, the thenar and hypothenar processes, after a symptomatic period in which scorching occurs. The soreness experienced by the patients limits their daily routines [4], and their quality of life is negatively impacted because of their incapacity to function in their hands and feet.
Hand-foot syndrome has been observed to occur during the second cycle of treatment [5]. There remains no currently effective treatment for this side effect today. Previous case reports indicate that henna may successfully safeguard against and halt the evolution of HFS [6, 7]. Henna (Lawsonia inermis L.) as a plant of the Myrtales order, classified under the Lythraceae family. Henna possesses a 9000-year history and has played a crucial role in herbal treatment since the Ayurvedic era [8]. Henna is a pigment derived from the desiccated bark and leaf of "Lawsonia inermis." Since the Lawsone molecule can combine with proteins, it is frequently used to color nails, the epidermis, hair, and clothing. Henna leaves are powdered, diluted in water or oil to make them stronger, and afterward applied to the skin, penetrating through the upper layer of the skin and turning a dark red color. It is a healthy and without side effects application. The growth and development inhibition of the extract on Candida albicans was identified in studies utilizing water, methanol, and chloroform extraction of henna leaves, and its antifungal activity was explained [9]. Until now, Hosein and Zinab's study revealed that water and methanol extracts of henna plant leaves possessed significant antioxidant qualities [8]. In another investigation that looked at antioxidant activity, the leaves were extracted with various solvents, and it was observed that chloroform extraction constructed the most activity [10].
Among the chemical components of the henna plant, Lawsone (LW), MCF-7, Caco-2, BJ, and Keratinocyte cells were evaluated for their efficacy in healing structurally damaged wounds. Various concentration principles might well be optimum in each cell line; the specificity of the LW compound to skin cells, particularly keratinocytes, is higher. While it can heal the wound in cells within as little as six hours, the utilization of the LW compound in the formulation of wound-treating products has been demonstrated with these results, when the control cell without LW has yet to attain 40% wound healing [11]. Besides that, it has been demonstrated in trials that coverings protected with Lawsone nano compound in the treatment of burns suppressed inflammation in the wound tissue and accelerated healing [10], and it was also reported in another study that it was beneficial in decubitus wounds [12]. As a result of the LW compound's antibacterial activity against Bacillus subtilis bacteria, it has been determined that the LW compound is suitable to be employed as an antibacterial agent in the struggle against this bacteria [13]. When henna was applied to a patient with pancreatic cancer and 2nd-degree hand-foot syndrome, HFS symptoms almost completely healed, and the patient's concerns such as burning, soreness, and incapacity to walk were abolished without dose limitation until the end of the treatment [14]. In another case study, Henna was applied to ten patients with metastatic breast and colon cancer who experienced HFS. Six patients had third-degree HFS before the study started, whereas four patients had second-degree HFS. Comprehensive improvement was noted in four patients with third-degree HFS, regression to first-degree level in two patients, and complete response in four patients with second-degree HFS as a consequence of henna treatment. It was recommended in these case reports to perform more experimental studies with more patients [15].
There is an explanation that there is a connection between the application of henna and the occurrence of hand-foot syndrome, and the purpose and progression of this interaction. The likely human links have not been completely clarified yet. Henna used in literature reviews has been found to have a substantial impact on reducing the occurrence of hand-foot syndrome. Capecitabine-induced HFS diminishes patients' quality of life and increases their need for medical attention. Patients who struggle to cope with their regular activities (feeding, personal hygiene, etc.) suffer from severe lesions on their feet and hands and may become dependent on others until the symptoms regress or subside. The need for effective treatments to avoid or decrease these symptoms reported in patients is mentioned in the literature [6-13] as much as possible. Although it has been determined that the majority of patients who received capecitabine were using henna as a protective against hand-foot syndrome according to the reports of nurses and researchers in chemotherapy clinics, our study aims to determine whether henna affects the symptoms. This nested case-control study (NCC) involving those receiving capecitabine treatment for breast and colorectal cancer was conducted to comprehensively examine the association between hand-foot syndrome and henna application. The NCC methodology in a prospective cohort research study is used when outcome data are accessible for all participants, although the exposure of interest has not been collected and is challenging or excessively costly to acquire for all patients. An NCC analysis employing comprehensive matching methods provides estimates that are equally efficient and unbiased as those derived from a complete cohort study. NCC with a reduced sample size is not only affordable but also less computationally intensive than analyzing the entire cohort study. If the matching technique has been performed correctly and the selected controls accurately represent those in the cohort research, then the Nested Case-Control (NCC) design has minimal loss of efficiency comparative to the full cohort analysis [16]. The NCC may provide superior validity compared to the whole cohort study due to its matching approach, which improves the adjustment for both measured and unmeasured factors.
- Conditions
- Henna, Hand-Foot Syndrome, Case-Control Study
- Being tested
- Henna
- Keywords
- Capecitabine, palmar-plantar erythrodysesthesia, symptom management, hand-foot syndrome
- Medical subject headings
- Hand-Foot Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HennaOther
Also called case group
The day-care unit of the University of Hacettepe's oncology hospital is being trained by educational nurses on the treatment of patients receiving capecitabine a day before the application of chemotherapy. All the patients were questioned about their individual and disease-related characteristics using the Patient Information Form, and The National Cancer Institute common terminology criteria for adverse events - version 4.03 (NCICTCAE v4.03), EORTC C30 Cancer Quality of Life Scale, and The Hand-Foot Syndrome-14 (HFS-14) were used by face-to-face interview technique.On the 21st day and the 63rd day after the first treatment course, patients who developed hand-foot syndrome constituted the case-control group, including patients who applied henna and patients who did not apply henna.
| Study group | Role | What they receive |
|---|---|---|
| Case group/Control group | In the data collection process, 84 patients received capecitabine and two patients (1:2) who met the inclusion criteria served as the control group (n=56, who received the test) for each case (n=28). Receives: Other: Henna |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effect of Interventions on Outcomes in the HFS Scores
Hand and foot symptoms scores were measured at the Baseline (T0), T1, and T2.
Measured: From enrollment to the end of treatment at 63 days
Secondary outcomes (1)
Effect of Interventions on Outcomes in the EORTC QLQ-C30 Scores
The case group and control group assessed the subdimension scores of the EORTC QLQ-C30.
Measured: From enrollment to the end of treatment at 63 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2025
- Study start15 Oct 2018
- Primary completion15 Dec 2018
- Study completion31 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for HennaStudies of the same condition, open and under way.
- More trials run by Hacettepe UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 84 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hacettepe University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Berna KURT, Hacettepe University
- Investigators
- Berna Kurt, Assistant professor, Principal investigator, Hacettepe University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06832501
- Sponsor's protocol ID
- KA-180085
- Acronym
- [Henna]
- Status last verified
- Feb 2025
- First submitted
- 6 Feb 2025
- Last updated
- 18 Feb 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: There is a plan to make IPD and related data dictionaries available.
Publications
Ngo LH, Inouye SK, Jones RN, Travison TG, Libermann TA, Dillon ST, Kuchel GA, Vasunilashorn SM, Alsop DC, Marcantonio ER. Methodologic considerations in the design and analysis of nested case-control studies: association between cytokines and postoperative delirium. BMC Med Res Methodol. 2017 Jun 6;17(1):88. doi: 10.1186/s12874-017-0359-8.
PubMed 28587598Yucel I, Guzin G. Topical henna for capecitabine induced hand-foot syndrome. Invest New Drugs. 2008 Apr;26(2):189-92. doi: 10.1007/s10637-007-9082-3. Epub 2007 Sep 21.
PubMed 17885735Ilyas S, Wasif K, Saif MW. Topical henna ameliorated capecitabine-induced hand-foot syndrome. Cutan Ocul Toxicol. 2014 Sep;33(3):253-5. doi: 10.3109/15569527.2013.832280. Epub 2013 Sep 11.
PubMed 24021017Habbal O, Hasson SS, El-Hag AH, Al-Mahrooqi Z, Al-Hashmi N, Al-Bimani Z, Al-Balushi MS, Al-Jabri AA. Antibacterial activity of Lawsonia inermis Linn (Henna) against Pseudomonas aeruginosa. Asian Pac J Trop Biomed. 2011 Jun;1(3):173-6. doi: 10.1016/S2221-1691(11)60021-X.
PubMed 23569753Hekmatpou D, Ahmadian F, Eghbali M, Farsaei S. Henna ( Lawsonia inermis) as an Inexpensive Method to Prevent Decubitus Ulcers in Critical Care Units: A Randomized Clinical Trial. J Evid Based Integr Med. 2018 Jan-Dec;23:2515690X18772807. doi: 10.1177/2515690X18772807.
PubMed 29756474A. Y. Kilcar, B. Cekic, F. Z. B. Muftuler, et al. ''In vitro evaluation of radiolabeled (125 I) methanol extracts of yarrow in cell lines of MCF-7, PC-3, A-549 and Caco-2,'' Journal of Radioanalytical and Nuclear Chemistry 295, no. 1 (2013): 593-599.
Hadisi Z, Nourmohammadi J, Nassiri SM. The antibacterial and anti-inflammatory investigation of Lawsonia Inermis-gelatin-starch nano-fibrous dressing in burn wound. Int J Biol Macromol. 2018 Feb;107(Pt B):2008-2019. doi: 10.1016/j.ijbiomac.2017.10.061. Epub 2017 Oct 13.
PubMed 29037870M. A. Saadabi, ''Evaluation of Lawsonia inermis Linn.(Sudanese henna) leaf extracts as an antimicrobial agent,'' Research Journal of Biological Sciences 2, no. 4 (2007): 419-423.
H. K. M. Hosein, D. Zinab, ''Phenolic compounds and antioxidant activity of henna leaf extracts (Lawsonia inermis),'' World Journal of Dairy & Food Sciences 2, no. 1 (2007): 38-41.
E. Karimi, B. Gharib, N. Rostami, L. Navidpour, and M. Afshar, ''Clinical efficacy of a topical polyherbal formulation in the management of fluorouracil-associated hand-foot syndrome,'' Journal of Herbal Medicine 17, (2019): 100270.
Pandy JGP, Franco PIG, Li RK. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Support Care Cancer. 2022 Nov;30(11):8655-8666. doi: 10.1007/s00520-022-07175-3. Epub 2022 Jun 2.
PubMed 35655045Jiang Z, Yang Y, Li L, Yue Z, Lan L, Pan Z. Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis. J Cancer Res Ther. 2018 Dec;14(Supplement):S957-S963. doi: 10.4103/0973-1482.187384.
PubMed 30539829Scontre VA, Martins JC, de Melo Sette CV, Mutti H, Cubero D, Fonseca F, Del Giglio A. Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study. J Diet Suppl. 2018 Sep 3;15(5):606-612. doi: 10.1080/19390211.2017.1366387. Epub 2017 Nov 2.
PubMed 29095653Basch E, Dueck AC, Rogak LJ, Mitchell SA, Minasian LM, Denicoff AM, Wind JK, Shaw MC, Heon N, Shi Q, Ginos B, Nelson GD, Meyers JP, Chang GJ, Mamon HJ, Weiser MR, Kolevska T, Reeve BB, Bruner DW, Schrag D. Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol. 2018 Sep 11;36(31):JCO2018788620. doi: 10.1200/JCO.2018.78.8620. Online ahead of print.
PubMed 30204536Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.
PubMed 28564564
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of the Henna Application in Patients With Hand-Foot Syndrome: Nested Case-Control Study
- ClinicalTrials.gov ID
- NCT06832501
- Acronym / sponsor ID
- [Henna] / KA-180085
- Conditions
- Henna, Hand-Foot Syndrome, Case-Control Study
- Keywords
- Capecitabine, palmar-plantar erythrodysesthesia, symptom management, hand-foot syndrome
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 84 participants (actual)
- Lead sponsor
- Hacettepe UniversityUniversity, hospital or other
- Study start
- 15 Oct 2018 (actual)
- Primary completion
- 15 Dec 2018 (actual)
- Study completion
- 31 Dec 2019 (actual)
- First posted
- 18 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction: There is an explanation that there is a connection between the application of henna and the occurrence of hand-foot syndrome, and the purpose and progression of this interaction. This nested case-control study of participants who underwent capecitabine therapy were breast and colorectal cancer was carried out to prospectively investigate the relationship of hand-foot syndrome with the henna application.
Method: Nested Case-Control (NCC) design within a longitudinal observational prospective cohort study in the setting of an oncology clinic. The primary outcome was hand-foot syndrome from in-hospital interviews and medical record reviews. In the data collection process, 84 patients received capecitabine and two patients (1:2) who met the inclusion criteria served as the control group (n=56, who received the test) for each case (n=28). The case and control groups were followed for 12 weeks. HFS-14 Scale and EORTC QLQ-C30 Quality of Life were conducted on the baseline, first follow-up (T1=day 21), and second follow-up (T2=day 63) cycles of chemotherapy. We used a non-parametric signed-rank test to test the median of paired differences.
Detailed description
Capecitabine is among the most effective treatments for metastatic or late-stage breast cancer. It is also another treatment approach for colorectal cancer. Capecitabine is a high-concentration 5-FU prodrug planned for thymidine phosphorylase enzyme primarily for two cancer types [1, 2]. Hand-foot syndrome (HFS), increasing skin pigmentation, diarrhea, nausea-vomiting, and fatigue are common side effects of the capecitabine treatment. According to phases 1 and 2 studies, the most common side effect of capecitabine is HFS, with a frequency that ranges from 10 to 50.7% [3]. HFS is a serious condition characterized by the accumulation of symmetrical, sharply contained, erythematous, edematous plaques, particularly on the lateral parts of the fingers, the thenar and hypothenar processes, after a symptomatic period in which scorching occurs. The soreness experienced by the patients limits their daily routines [4], and their quality of life is negatively impacted because of their incapacity to function in their hands and feet.
Hand-foot syndrome has been observed to occur during the second cycle of treatment [5]. There remains no currently effective treatment for this side effect today. Previous case reports indicate that henna may successfully safeguard against and halt the evolution of HFS [6, 7]. Henna (Lawsonia inermis L.) as a plant of the Myrtales order, classified under the Lythraceae family. Henna possesses a 9000-year history and has played a crucial role in herbal treatment since the Ayurvedic era [8]. Henna is a pigment derived from the desiccated bark and leaf of "Lawsonia inermis." Since the Lawsone molecule can combine with proteins, it is frequently used to color nails, the epidermis, hair, and clothing. Henna leaves are powdered, diluted in water or oil to make them stronger, and afterward applied to the skin, penetrating through the upper layer of the skin and turning a dark red color. It is a healthy and without side effects application. The growth and development inhibition of the extract on Candida albicans was identified in studies utilizing water, methanol, and chloroform extraction of henna leaves, and its antifungal activity was explained [9]. Until now, Hosein and Zinab's study revealed that water and methanol extracts of henna plant leaves possessed significant antioxidant qualities [8]. In another investigation that looked at antioxidant activity, the leaves were extracted with various solvents, and it was observed that chloroform extraction constructed the most activity [10].
Among the chemical components of the henna plant, Lawsone (LW), MCF-7, Caco-2, BJ, and Keratinocyte cells were evaluated for their efficacy in healing structurally damaged wounds. Various concentration principles might well be optimum in each cell line; the specificity of the LW compound to skin cells, particularly keratinocytes, is higher. While it can heal the wound in cells within as little as six hours, the utilization of the LW compound in the formulation of wound-treating products has been demonstrated with these results, when the control cell without LW has yet to attain 40% wound healing [11]. Besides that, it has been demonstrated in trials that coverings protected with Lawsone nano compound in the treatment of burns suppressed inflammation in the wound tissue and accelerated healing [10], and it was also reported in another study that it was beneficial in decubitus wounds [12]. As a result of the LW compound's antibacterial activity against Bacillus subtilis bacteria, it has been determined that the LW compound is suitable to be employed as an antibacterial agent in the struggle against this bacteria [13]. When henna was applied to a patient with pancreatic cancer and 2nd-degree hand-foot syndrome, HFS symptoms almost completely healed, and the patient's concerns such as burning, soreness, and incapacity to walk were abolished without dose limitation until the end of the treatment [14]. In another case study, Henna was applied to ten patients with metastatic breast and colon cancer who experienced HFS. Six patients had third-degree HFS before the study started, whereas four patients had second-degree HFS. Comprehensive improvement was noted in four patients with third-degree HFS, regression to first-degree level in two patients, and complete response in four patients with second-degree HFS as a consequence of henna treatment. It was recommended in these case reports to perform more experimental studies with more patients [15].
There is an explanation that there is a connection between the application of henna and the occurrence of hand-foot syndrome, and the purpose and progression of this interaction. The likely human links have not been completely clarified yet. Henna used in literature reviews has been found to have a substantial impact on reducing the occurrence of hand-foot syndrome. Capecitabine-induced HFS diminishes patients' quality of life and increases their need for medical attention. Patients who struggle to cope with their regular activities (feeding, personal hygiene, etc.) suffer from severe lesions on their feet and hands and may become dependent on others until the symptoms regress or subside. The need for effective treatments to avoid or decrease these symptoms reported in patients is mentioned in the literature [6-13] as much as possible. Although it has been determined that the majority of patients who received capecitabine were using henna as a protective against hand-foot syndrome according to the reports of nurses and researchers in chemotherapy clinics, our study aims to determine whether henna affects the symptoms. This nested case-control study (NCC) involving those receiving capecitabine treatment for breast and colorectal cancer was conducted to comprehensively examine the association between hand-foot syndrome and henna application. The NCC methodology in a prospective cohort research study is used when outcome data are accessible for all participants, although the exposure of interest has not been collected and is challenging or excessively costly to acquire for all patients. An NCC analysis employing comprehensive matching methods provides estimates that are equally efficient and unbiased as those derived from a complete cohort study. NCC with a reduced sample size is not only affordable but also less computationally intensive than analyzing the entire cohort study. If the matching technique has been performed correctly and the selected controls accurately represent those in the cohort research, then the Nested Case-Control (NCC) design has minimal loss of efficiency comparative to the full cohort analysis [16]. The NCC may provide superior validity compared to the whole cohort study due to its matching approach, which improves the adjustment for both measured and unmeasured factors.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Case group/Control group | – | Other: HennaIn the data collection process, 84 patients received capecitabine and two patients (1:2) who met the inclusion criteria served as the control group (n=56, who received the test) for each case (n=28). |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- In the data collection process, 28 patients received capecitabine treatment at the Hacettepe University Hospital of Oncology meeting the research criteria and two patients (n=56, who received the test) who met the inclusion criteria served as the control group for each case. (1:2). Controls were matched with patients in a ratio of two to one depending on age at collection of samples (+3), gender, body surface area index, and skin type data. Minimum number of samples achieved under at least 5% type error and at least 95% power condition. The study used the initial non-development of EAS as a criterion for the HFS scale score, which was studied between "grade 0" and "grade 3" according to the NIC-CTCAE criteria, and was between 18 and 65 years of age.
Key inclusion criteria (6 listed)
- Would be getting capecitabine as chemotherapy,
- Were aged between 18 and 65,
- Had a diagnosis of either breast or cancer of the colorectal
- Were willing to communicate, literate, and were informed about their diagnosis,
- Were not using psychotropic drugs, anxiolytic, antidepressant, analgesic, or sedative medications,
Key exclusion criteria (5 listed)
- Were undergoing radiation,
- Were taking supplements such as vitamin E,
- Had previously had capecitabine treatment,
- Had damage to the skin on their hands or feet,
- Were unwilling to voluntarily engage in the trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HennaAlso: case groupThe day-care unit of the University of Hacettepe's oncology hospital is being trained by educational nurses on the treatment of patients receiving capecitabine a day before the application of chemotherapy. All the patients were questioned about their individual and disease-related characteristics using the Patient Information Form, and The National Cancer Institute common terminology criteria for adverse events - version 4.03 (NCICTCAE v4.03), EORTC C30 Cancer Quality of Life Scale, and The Hand-Foot Syndrome-14 (HFS-14) were used by face-to-face interview technique.On the 21st day and the 63rd day after the first treatment course, patients who developed hand-foot syndrome constituted the case-control group, including patients who applied henna and patients who did not apply henna. | Other | Case group/Control group |
Primary outcome
Effect of Interventions on Outcomes in the HFS Scores
Time frame: From enrollment to the end of treatment at 63 days
Hand and foot symptoms scores were measured at the Baseline (T0), T1, and T2.
1 secondary outcome
Effect of Interventions on Outcomes in the EORTC QLQ-C30 Scores
Time frame: From enrollment to the end of treatment at 63 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2025.
- Results publication: PubMed 28587598Ngo LH, Inouye SK, Jones RN, Travison TG, Libermann TA, Dillon ST, Kuchel GA, Vasunilashorn SM, Alsop DC, Marcantonio ER. Methodologic considerations in the design and analysis of nested case-control studies: association between cytokines and postoperative delirium. BMC Med Res Methodol. 2017 Jun 6;17(1):88. doi: 10.1186/s12874-017-0359-8.
- Results publication: PubMed 17885735Yucel I, Guzin G. Topical henna for capecitabine induced hand-foot syndrome. Invest New Drugs. 2008 Apr;26(2):189-92. doi: 10.1007/s10637-007-9082-3. Epub 2007 Sep 21.
- Results publication: PubMed 24021017Ilyas S, Wasif K, Saif MW. Topical henna ameliorated capecitabine-induced hand-foot syndrome. Cutan Ocul Toxicol. 2014 Sep;33(3):253-5. doi: 10.3109/15569527.2013.832280. Epub 2013 Sep 11.
- Results publication: PubMed 23569753Habbal O, Hasson SS, El-Hag AH, Al-Mahrooqi Z, Al-Hashmi N, Al-Bimani Z, Al-Balushi MS, Al-Jabri AA. Antibacterial activity of Lawsonia inermis Linn (Henna) against Pseudomonas aeruginosa. Asian Pac J Trop Biomed. 2011 Jun;1(3):173-6. doi: 10.1016/S2221-1691(11)60021-X.
- Results publication: PubMed 29756474Hekmatpou D, Ahmadian F, Eghbali M, Farsaei S. Henna ( Lawsonia inermis) as an Inexpensive Method to Prevent Decubitus Ulcers in Critical Care Units: A Randomized Clinical Trial. J Evid Based Integr Med. 2018 Jan-Dec;23:2515690X18772807. doi: 10.1177/2515690X18772807.
- Results publicationA. Y. Kilcar, B. Cekic, F. Z. B. Muftuler, et al. ''In vitro evaluation of radiolabeled (125 I) methanol extracts of yarrow in cell lines of MCF-7, PC-3, A-549 and Caco-2,'' Journal of Radioanalytical and Nuclear Chemistry 295, no. 1 (2013): 593-599.
- Results publication: PubMed 29037870Hadisi Z, Nourmohammadi J, Nassiri SM. The antibacterial and anti-inflammatory investigation of Lawsonia Inermis-gelatin-starch nano-fibrous dressing in burn wound. Int J Biol Macromol. 2018 Feb;107(Pt B):2008-2019. doi: 10.1016/j.ijbiomac.2017.10.061. Epub 2017 Oct 13.
- Results publicationM. A. Saadabi, ''Evaluation of Lawsonia inermis Linn.(Sudanese henna) leaf extracts as an antimicrobial agent,'' Research Journal of Biological Sciences 2, no. 4 (2007): 419-423.
- Results publicationH. K. M. Hosein, D. Zinab, ''Phenolic compounds and antioxidant activity of henna leaf extracts (Lawsonia inermis),'' World Journal of Dairy & Food Sciences 2, no. 1 (2007): 38-41.
- Results publicationE. Karimi, B. Gharib, N. Rostami, L. Navidpour, and M. Afshar, ''Clinical efficacy of a topical polyherbal formulation in the management of fluorouracil-associated hand-foot syndrome,'' Journal of Herbal Medicine 17, (2019): 100270.
- Results publication: PubMed 35655045Pandy JGP, Franco PIG, Li RK. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Support Care Cancer. 2022 Nov;30(11):8655-8666. doi: 10.1007/s00520-022-07175-3. Epub 2022 Jun 2.
- Results publication: PubMed 30539829Jiang Z, Yang Y, Li L, Yue Z, Lan L, Pan Z. Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis. J Cancer Res Ther. 2018 Dec;14(Supplement):S957-S963. doi: 10.4103/0973-1482.187384.
- Individual participant dataSharing planned: Yes. There is a plan to make IPD and related data dictionaries available.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Berna Kurt, Assistant professor principal investigator
Hacettepe University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Henna and Hand-Foot Syndrome, run by Hacettepe University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effect of Interventions on Outcomes in the HFS Scores (time frame: From enrollment to the end of treatment at 63 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06832501, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2025.